newsfilter
← Latest News
GlobeNewswire·

Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update

Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004 trial in rapid